PMID- 36965471
OWN - NLM
STAT- MEDLINE
DCOM- 20230619
LR  - 20231121
IS  - 1943-569X (Electronic)
IS  - 0003-1488 (Linking)
VI  - 261
IP  - 7
DP  - 2023 Jul 1
TI  - Comparison of caregivers' assessments of clinical outcome in dogs with idiopathic 
      epilepsy administered levetiracetam, zonisamide, or phenobarbital monotherapy.
PG  - 1020-1027
LID - 10.2460/javma.22.10.0469 [doi]
AB  - OBJECTIVE: To investigate caregivers' assessments of outcome in dogs with 
      idiopathic epilepsy (IE) administered levetiracetam (LEV), zonisamide (ZNS), or 
      phenobarbital (PB) monotherapy. ANIMALS: 100 dogs with IE administered LEV (n = 
      34), ZNS (31), or PB (35) monotherapy between January 1, 2003, and February 6, 
      2019, and survey responses from their caregivers. PROCEDURES: Information on 
      duration of therapy, adverse effects (AEs), and outcome was obtained from medical 
      record review and caregiver questionnaire. RESULTS: A significant improvement in 
      mean quality of life score was reported during monotherapy (7.7; SD, 2.14) 
      compared to before treatment (6.25; SD, 2.63; P < .0001), with no difference 
      identified between monotherapy groups. Compared to ZNS monotherapy, dogs 
      prescribed PB monotherapy had a significantly younger median age at seizure onset 
      (2.6 vs 4.3 years; P = .024). A significant relationship was identified between 
      the occurrence of reported AEs and monotherapy group, with a higher prevalence in 
      the PB group (77% [27/35]) and a lower prevalence in the ZNS group (39% [12/31]; 
      P = .0066). Treatment failure rates for PB, LEV, and ZNS monotherapy were 51%, 
      35%, and 45%, respectively, with failure attributed most commonly to inadequate 
      seizure control. No significant difference was identified between groups with 
      respect to rate of or time to failure. CLINICAL RELEVANCE: Most caregivers 
      reported a favorable outcome with administration of LEV, ZNS, or PB monotherapy 
      to dogs with IE. Phenobarbital is associated with the highest prevalence of AEs 
      but no difference in quality of life score. Prospective controlled studies are 
      needed to further compare the efficacy and safety of these monotherapies in dogs 
      with IE.
FAU - Gristina, Bryanna R
AU  - Gristina BR
FAU - Waldron, Rennie J
AU  - Waldron RJ
FAU - Nettifee, Julie A
AU  - Nettifee JA
FAU - Munana, Karen R
AU  - Munana KR
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230323
PL  - United States
TA  - J Am Vet Med Assoc
JT  - Journal of the American Veterinary Medical Association
JID - 7503067
RN  - 44YRR34555 (Levetiracetam)
RN  - 459384H98V (Zonisamide)
RN  - 0 (Anticonvulsants)
RN  - KPS085631O (zinc sulfide)
RN  - YQE403BP4D (Phenobarbital)
SB  - IM
MH  - Dogs
MH  - Animals
MH  - Humans
MH  - Levetiracetam/therapeutic use
MH  - Zonisamide/therapeutic use
MH  - Anticonvulsants/adverse effects
MH  - Caregivers
MH  - Prospective Studies
MH  - Quality of Life
MH  - *Epilepsy/drug therapy/veterinary
MH  - Phenobarbital/therapeutic use
MH  - Seizures/veterinary
MH  - *Dog Diseases/drug therapy/chemically induced
EDAT- 2023/03/26 06:00
MHDA- 2023/06/19 13:08
CRDT- 2023/03/25 19:32
PHST- 2022/10/31 00:00 [received]
PHST- 2023/03/01 00:00 [accepted]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/03/26 06:00 [pubmed]
PHST- 2023/03/25 19:32 [entrez]
AID - 10.2460/javma.22.10.0469 [doi]
PST - epublish
SO  - J Am Vet Med Assoc. 2023 Mar 23;261(7):1020-1027. doi: 10.2460/javma.22.10.0469. 
      Print 2023 Jul 1.